thiopurine S-methyltransferase
Last updated 17 Jul 2023
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The TPMT gene provides instructions for making an enzyme called thiopurine S-methyltransferase (TPMT). This enzyme carries out a specific chemical reaction called S-methylation of a group of molecules known as aromatic and heterocyclic sulphydryl compounds. This function is of particular interest because it is critical for breaking down (metabolizing) drugs called thiopurines. These drugs, which include 6-thioguanine, 6-mercaptopurine, and azathioprine, inhibit (suppress) the body's immune system. They are used to treat several forms of cancer and other disorders involving immune system malfunction, such as Crohn's disease and rheumatoid arthritis. Thiopurine drugs are also used in organ transplant recipients to help prevent the immune system from attacking the transplanted organ.
Video picks for GenesVideo library
Normal function
The TPMT gene provides instructions for making an enzyme called thiopurine S-methyltransferase (TPMT). This enzyme carries out a specific chemical reaction called S-methylation of a group of molecules known as aromatic and heterocyclic sulphydryl compounds. This function is of particular interest because it is critical for breaking down (metabolizing) drugs called thiopurines. These drugs, which include 6-thioguanine, 6-mercaptopurine, and azathioprine, inhibit (suppress) the body's immune system. They are used to treat several forms of cancer and other disorders involving immune system malfunction, such as Crohn's disease and rheumatoid arthritis. Thiopurine drugs are also used in organ transplant recipients to help prevent the immune system from attacking the transplanted organ.
Once inside the body, thiopurine drugs are converted to toxic compounds that kill immune system cells in the bone marrow. The TPMT enzyme "turns off" thiopurine drugs by metabolizing them to inactive, nontoxic compounds.
Conditions referring to this gene or chromosome
Other names
S-adenosyl-L-methionine:thiopurine S-methyltransferase
thiopurine methyltransferase
TPMT_HUMAN
Patient picks for Genes

Yorkshire talks series 2
Jono Lancaster: From Treacher Collins to Global Inspiration | Yorkshire Talks S2
In this powerful and deeply moving episode, Matt and Christine sit down with Yorkshire-born inspiration Jono Lancaster, whose remarkable journey has touched hearts across the world. Known for his uplifting memoir Not All Heroes Wear Capes and his recent role hosting Channel 4’s Love My Face, Jono brings honesty, warmth, and courage to every part of his story. 🎙 Jono Lancaster in Yorkshire Talks: The Journey to Joy & Acceptance Jono opens up about living with Treacher Collins Syndrome, a condition that affects his facial appearance. Fostered at just two weeks old when his biological parents felt unable to cope, he shares how those early experiences shaped his sense of identity, belonging, and resilience in profound ways. Today, Jono travels the world delivering empowering talks, meeting families, and championing visibility, confidence, and compassion — always with his trademark humour and heartfelt honesty. 🌍 From Yorkshire to Global Advocate Jono reveals what it’s like to speak to audiences worldwide, spread his message of self-love, and connect with people who see themselves in his story. He talks about the impact of writing his memoir, how it changed his own perspective, and how he stepped into TV presenting with Love My Face, bringing representation to an even bigger audience. 💙 Facing Challenges, Finding Light This conversation dives into the emotional realities of growing up feeling “different,” and how Jono turned pain into purpose. He reflects on the people who helped him find joy, the moments that tested him, and the mindset that allowed him to embrace who he is — fully and unapologetically. 😊 Inspiring, emotional, unforgettable — Jono at his very best Jono’s story is inspiring, life-affirming, and impossible to forget. By the end of this episode, we guarantee you’ll be as moved, empowered, and uplifted as everyone who has the privilege of meeting him. 👍 If you enjoy this episode, please like and subscribe for more inspiring conversations throughout Series Two of Yorkshire Talks!

Yorkshire talks series 2
Matt Jameson & Christine Talbot Interview Each Other! | Meet the Hosts of Yorkshire Talks
Ahead of the launch of Series Two of Yorkshire Talks, hosts Matt Jameson and Christine Talbot sit down for a very special episode — they’re interviewing each other! If you’ve ever wondered who they are behind the mic, this is the perfect place to start. ⭐ Who is Matt Jameson? Born and raised in Yorkshire, Matt opens up about his journey in the charity sector, his experience coming out to his parents, and his life-changing role in the first-ever gay marriage on Channel 4’s Married at First Sight UK. He speaks honestly about navigating sudden national and international fame, his mental health journey, the ups and downs of love, and the support of his close-knit Yorkshire family. ⭐ Who is Christine Talbot? With a 30-year career as one of the most recognisable faces on TV in Yorkshire and Lincolnshire, Christine reflects on her decades in live broadcasting and the extraordinary stories she’s covered. She talks candidly about her cancer diagnosis, how the pandemic reshaped her life, and her decision to embark on a fresh chapter. Christine also shares a remarkable family story, including her husband’s role in finally closing the chapter on the mystery of “Wearside Jack,” the hoaxer who derailed the Yorkshire Ripper investigation. 🚀 Catch Up Before Series Two Arrives With Series Two of Yorkshire Talks coming soon, now’s the perfect time to get to know your hosts on a deeper level. If you love Yorkshire stories, inspiring guests, and honest conversation, you won’t want to miss what’s coming next. 👍 Please like and subscribe so you never miss an episode or our exciting upcoming line-up of guests.
Related patient information and medicines

Patient information leaflet
Parkinson's disease
However, if you take an MAO-B inhibitor at first, it may delay the need for levodopa for months or years. Sometimes these medicines are used in combination with levodopa in the later stages of PD. Other medicines used for PD Catechol-O-methyltransferase (COMT) inhibitors are relatively new medicines. They include tolcapone Tolcapone for.

Medicine leaflet
Tioguanine
You will be prescribed tioguanine by a doctor who specialises in cancer treatment. Tioguanine is a treatment used for acute myeloid leukaemia (AML) , acute lymphoblastic leukaemia (ALL) , and chronic myeloid leukaemia (CML). If you have ever been told by a doctor that you lack certain enzymes... In particular, tell your doctor if you know your.

Medicine leaflet
Mercaptopurine
You will be prescribed mercaptopurine by a specialist cancer doctor. Mercaptopurine is a treatment used for acute myeloid leukaemia (AML) , acute lymphoblastic leukaemia (ALL) , and chronic myeloid leukaemia (CML). If you have ever been told by a doctor that you lack certain enzymes which hel... In particular, tell your doctor if you know your.

Medicine leaflet
Entacapone for Parkinson's disease
About entacapone Type of medicine A dopaminergic medicine called a catechol-O-methyltransferase inhibitor Used for Parkinson's disease Also called Comtess®; Combination brands: Stalevo®, Sastravi®, Stanek®, Lecigon® (entacapone with levodopa and carbidopa [ co-careldopa Co-careldopa for Parkinson's disease ]) Available as Tablets Parkinson's.

Medicine leaflet
Tolcapone for Parkinson's disease
Tolcapone will be recommended for you by a specialist doctor who will continue to check on your progress. You should te... About tolcapone Type of medicine A dopaminergic medicine called a catechol-O-methyltransferase inhibitor Used for Parkinson's disease Also called Tasmar® Available as Tablets Parkinson's disease Parkinson's disease affects the.
Further reading and references
- thiopurine S-methyltransferase; MedlinePlus, National Library of Medicine.
- Appell ML, Berg J, Duley J, Evans WE, Kennedy MA, Lennard L, Marinaki T, McLeod HL, Relling MV, Schaeffeler E, Schwab M, Weinshilboum R, Yeoh AE, McDonagh EM, Hebert JM, Klein TE, Coulthard SA. Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics. 2013 Apr;23(4):242-8. doi: 10.1097/FPC.0b013e32835f1cc0.
- Coulthard S, Hogarth L. The thiopurines: an update. Invest New Drugs. 2005 Dec;23(6):523-32. doi: 10.1007/s10637-005-4020-8.
- Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem Pharmacol. 2010 May 1;79(9):1211-20. doi: 10.1016/j.bcp.2010.01.006. Epub 2010 Jan 21.
- Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011 Mar;89(3):387-91. doi: 10.1038/clpt.2010.320. Epub 2011 Jan 26.
- Wang L, Pelleymounter L, Weinshilboum R, Johnson JA, Hebert JM, Altman RB, Klein TE. Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenet Genomics. 2010 Jun;20(6):401-5. doi: 10.1097/FPC.0b013e3283352860. No abstract available.
- Zaza G, Cheok M, Krynetskaia N, Thorn C, Stocco G, Hebert JM, McLeod H, Weinshilboum RM, Relling MV, Evans WE, Klein TE, Altman RB. Thiopurine pathway. Pharmacogenet Genomics. 2010 Sep;20(9):573-4. doi: 10.1097/FPC.0b013e328334338f. No abstract available.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

